Naomi K. Tepper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naomi K. Tepper has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Kathryn M. Curtis
Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA
26 shared publicationsPolly A. Marchbanks
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia
18 shared publicationsMaura K. Whiteman
Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA
14 shared publications- Denise J. Jamieson
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
8 shared publications Lauren B. Zapata
Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA
7 shared publications- Kathryn M. Curtis
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
5 shared publications
Latest Publications
- 1 July 2020
- Published by Elsevier in Contraception
- Vol. 102 (1) , 34-38
Physician and clinic staff attitudes and practices during implementation of the Zika Contraception Access Network
- 1 July 2020
- Published by Elsevier in Contraception
- Vol. 102 (1) , 34-38
Physician and clinic staff attitudes and practices during implementation of the Zika Contraception Access Network
- 10 April 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (14) , 405-410
Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection
Women at high risk for human immunodeficiency virus are eligible to use all hormonal contraceptive methods and intrauterine devices.
- 10 April 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (14) , 405-410
Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection
Women at high risk for human immunodeficiency virus are eligible to use all hormonal contraceptive methods and intrauterine devices.
- 1 March 2020
- Published by Elsevier in Women's Health Issues
- Vol. 30 (2) , 98-105
Intimate Partner Violence around the Time of Pregnancy and Postpartum Contraceptive Use
- 1 March 2020
- Published by Elsevier in Women's Health Issues
- Vol. 30 (2) , 98-105
Intimate Partner Violence around the Time of Pregnancy and Postpartum Contraceptive Use
- 1 December 2019
- Published by Elsevier in Contraception
- Vol. 100 (6) , 474-479
Description and comparison of postpartum use of effective contraception among women with and without diabetes
- 1 December 2019
- Published by Elsevier in Contraception
- Vol. 100 (6) , 474-479
Description and comparison of postpartum use of effective contraception among women with and without diabetes
- 8 May 2019
- Published by Springer Nature in Maternal and Child Health Journal
- Vol. 23 (8) , 1079-1086
Health Care Provider Attitudes Toward Safety of Selected Hormonal Contraceptives in Breastfeeding Women
ObjectivesLittle is known about provider attitudes regarding safety of selected hormonal contraceptives among breastfeeding women.MethodsUsing a nationwide survey, associations were analyzed between provider characteristics and perception of safety of combined oral contraceptives (COCs) in breastfeeding women1 month postpartum without other venous thrombosis risk factors and depot medroxyprogesterone acetate (DMPA) in breastfeeding women<1 month postpartum and 1 month postpartum.ResultsApproximately 68% of public-sector providers considered COCs safe for breastfeeding women1 month postpartum without other venous thrombosis risk factors, with lower odds among non-physicians versus physicians (adjusted odds ratios [aOR] range 0.34-0.51) and those with a focus on adolescent health/pediatrics versus reproductive health (aOR 0.68, 95% confidence interval [CI] 0.47-0.99). Most public-sector providers considered DMPA safe for breastfeeding women during any time postpartum, with lower odds among non-physicians versus physicians (aOR range 0.20-0.54) and those with primary clinical focus other than reproductive health (aOR range 0.26-0.65). The majority of office-based physicians considered COCs safe for breastfeeding women1 month postpartum without other venous thrombosis risk factors, with lower odds among those who did not use, versus those who used, CDC's contraceptive guidance (aOR 0.40, 95% CI 0.21-0.77). Most office-based physicians also considered DMPA safe for breastfeeding women during any time postpartum.Conclusions for PracticeA high proportion of providers considered use of selected hormonal contraceptives safe for breastfeeding women, consistent with evidence-based guidelines. However, certain provider groups might benefit from education regarding the safety of these methods for breastfeeding women.
- 8 May 2019
- Published by Springer Nature in Maternal and Child Health Journal
- Vol. 23 (8) , 1079-1086
Health Care Provider Attitudes Toward Safety of Selected Hormonal Contraceptives in Breastfeeding Women
ObjectivesLittle is known about provider attitudes regarding safety of selected hormonal contraceptives among breastfeeding women.MethodsUsing a nationwide survey, associations were analyzed between provider characteristics and perception of safety of combined oral contraceptives (COCs) in breastfeeding women1 month postpartum without other venous thrombosis risk factors and depot medroxyprogesterone acetate (DMPA) in breastfeeding women<1 month postpartum and 1 month postpartum.ResultsApproximately 68% of public-sector providers considered COCs safe for breastfeeding women1 month postpartum without other venous thrombosis risk factors, with lower odds among non-physicians versus physicians (adjusted odds ratios [aOR] range 0.34-0.51) and those with a focus on adolescent health/pediatrics versus reproductive health (aOR 0.68, 95% confidence interval [CI] 0.47-0.99). Most public-sector providers considered DMPA safe for breastfeeding women during any time postpartum, with lower odds among non-physicians versus physicians (aOR range 0.20-0.54) and those with primary clinical focus other than reproductive health (aOR range 0.26-0.65). The majority of office-based physicians considered COCs safe for breastfeeding women1 month postpartum without other venous thrombosis risk factors, with lower odds among those who did not use, versus those who used, CDC's contraceptive guidance (aOR 0.40, 95% CI 0.21-0.77). Most office-based physicians also considered DMPA safe for breastfeeding women during any time postpartum.Conclusions for PracticeA high proportion of providers considered use of selected hormonal contraceptives safe for breastfeeding women, consistent with evidence-based guidelines. However, certain provider groups might benefit from education regarding the safety of these methods for breastfeeding women.
- 1 March 2019
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 133 (3) , 533-540
Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum
OBJECTIVE: To estimate the absolute and relative risk of venous thromboembolism (VTE) among women who initiate depot medroxyprogesterone acetate (DMPA) immediately postpartum compared with those who do not initiate hormonal contraception. METHODS: The IBM MarketScan Commercial Claims and Encounters databases were used to identify delivery hospitalizations among women aged 15–44 years during 2005 through 2014. Diagnosis, procedure, and drug codes were used to identify contraception, VTE, and potential confounding chronic or pregnancy-related conditions. Women who initiated DMPA during days 0 through 7 postpartum were compared with women who did not initiate hormonal contraception during days 0 through 7 postpartum. Women were followed from date of delivery through 12 weeks postpartum for the occurrence of VTE, with censoring at hormonal contraception initiation or prescription, hysterectomy, sterilization, or inpatient death. The incidence rate of VTE and 95% CIs were calculated within each group and the incidence rate ratio was calculated comparing the two groups. RESULTS: The unadjusted VTE incidence rate through 12 weeks postpartum was 0.42/10,000 women-days in the immediate postpartum DMPA group (34 events among 11,159 women contributing 805,999 days of follow-up) and 0.15/10,000 women-days in the control group (3,107 events among 3,102,011 women contributing 206,180,811 days of follow-up). The incidence rate ratio for VTE was 2.87 (95% CI 2.05–4.03) among women in the immediate postpartum DMPA group compared with women in the control group, adjusting for age alone. After adjusting for age and pregnancy-related and chronic conditions, the adjusted incidence rate ratio for VTE was 1.94 (95% CI 1.38–2.72) among women in the immediate postpartum DMPA group compared with women in the control group. CONCLUSION: Initiation of DMPA immediately postpartum is associated with a low incidence but an increased relative risk of VTE compared with nonuse of hormonal contraception.
- 1 March 2019
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 133 (3) , 533-540
Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum
OBJECTIVE: To estimate the absolute and relative risk of venous thromboembolism (VTE) among women who initiate depot medroxyprogesterone acetate (DMPA) immediately postpartum compared with those who do not initiate hormonal contraception. METHODS: The IBM MarketScan Commercial Claims and Encounters databases were used to identify delivery hospitalizations among women aged 15–44 years during 2005 through 2014. Diagnosis, procedure, and drug codes were used to identify contraception, VTE, and potential confounding chronic or pregnancy-related conditions. Women who initiated DMPA during days 0 through 7 postpartum were compared with women who did not initiate hormonal contraception during days 0 through 7 postpartum. Women were followed from date of delivery through 12 weeks postpartum for the occurrence of VTE, with censoring at hormonal contraception initiation or prescription, hysterectomy, sterilization, or inpatient death. The incidence rate of VTE and 95% CIs were calculated within each group and the incidence rate ratio was calculated comparing the two groups. RESULTS: The unadjusted VTE incidence rate through 12 weeks postpartum was 0.42/10,000 women-days in the immediate postpartum DMPA group (34 events among 11,159 women contributing 805,999 days of follow-up) and 0.15/10,000 women-days in the control group (3,107 events among 3,102,011 women contributing 206,180,811 days of follow-up). The incidence rate ratio for VTE was 2.87 (95% CI 2.05–4.03) among women in the immediate postpartum DMPA group compared with women in the control group, adjusting for age alone. After adjusting for age and pregnancy-related and chronic conditions, the adjusted incidence rate ratio for VTE was 1.94 (95% CI 1.38–2.72) among women in the immediate postpartum DMPA group compared with women in the control group. CONCLUSION: Initiation of DMPA immediately postpartum is associated with a low incidence but an increased relative risk of VTE compared with nonuse of hormonal contraception.
- 1 April 2018
- Published by SAGE Publications in Journal of Women's Health
- Vol. 27 (4) , 413-417
Hormonal Contraceptive Use Among Women of Older Reproductive Age: Considering Risks and Benefits
As women approach menopause, fertility declines but pregnancy can still occur. Maternal and infant risks are increased among women of older reproductive age compared with younger women. A high proportion of pregnancies among women of older reproductive age are unintended and these pregnancies can also be associated with negative maternal and infant consequences. However, women and their healthcare providers may have concerns about risks associated with contraceptive use, particularly combined hormonal contraceptives, among women of older reproductive age who already may be at increased risk for conditions such as cardiovascular disease and breast cancer. Nonetheless, available evidence does not suggest that hormonal contraceptive use among women of older reproductive age substantially increases age-related risks of cardiovascular events or breast cancer. CDC recommends that contraception is still needed for women older than 44 years who have not reached menopause and wish to avoid pregnancy, and that based on age alone, all contraceptive methods are considered safe or generally safe for use by women of older reproductive age.
- 1 April 2018
- Published by SAGE Publications in Journal of Women's Health
- Vol. 27 (4) , 413-417
Hormonal Contraceptive Use Among Women of Older Reproductive Age: Considering Risks and Benefits
As women approach menopause, fertility declines but pregnancy can still occur. Maternal and infant risks are increased among women of older reproductive age compared with younger women. A high proportion of pregnancies among women of older reproductive age are unintended and these pregnancies can also be associated with negative maternal and infant consequences. However, women and their healthcare providers may have concerns about risks associated with contraceptive use, particularly combined hormonal contraceptives, among women of older reproductive age who already may be at increased risk for conditions such as cardiovascular disease and breast cancer. Nonetheless, available evidence does not suggest that hormonal contraceptive use among women of older reproductive age substantially increases age-related risks of cardiovascular events or breast cancer. CDC recommends that contraception is still needed for women older than 44 years who have not reached menopause and wish to avoid pregnancy, and that based on age alone, all contraceptive methods are considered safe or generally safe for use by women of older reproductive age.
- 1 March 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (3) , 364-365
Reply
- 1 March 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (3) , 364-365
Reply
- Top Cited PapersOpen Access
- 22 February 2018
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 141 (3) , 287-294
A systematic review and meta‐analysis of venous thrombosis risk among users of combined oral contraception
Background: Combined oral contraceptives (COCs) containing various progestogens could be associated with differential risks for venous thromboembolism (VTE).Objective: To evaluate the comparative risks of VTE associated with the use of low‐dose (less than 50 μg ethinyl estradiol) COCs containing different progestogens.Search strategy: PubMed and the Cochrane Library were searched from database inception through September 15, 2016, by combining search terms for oral contraception and venous thrombosis.Selection criteria: Studies reporting VTE risk estimates among healthy users of progestogen‐containing low‐dose COCs were included.Data collection and analysis: A random‐effects model was used to generate pooled adjusted risk ratios and 95% confidence intervals; subgroup and sensitivity analyses assessed the impact of monophasic‐COC use and study‐level characteristics.Main results: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel‐containing COCs (pooled risk ratios 1.5–2.0). The analysis restricted to monophasic COC formulations with 30 μg of ethinyl estradiol yielded similar findings. After adjustment for study characteristics, the risk estimates were slightly attenuated.Conclusions: Compared with the use of levonorgestrel‐containing COCs, the use of COCs containing other progestogens could be associated with a small increase in risk for VTE.
- 22 February 2018
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 141 (3) , 287-294
Top Cited PapersOpen AccessA systematic review and meta‐analysis of venous thrombosis risk among users of combined oral contraception
Background: Combined oral contraceptives (COCs) containing various progestogens could be associated with differential risks for venous thromboembolism (VTE).Objective: To evaluate the comparative risks of VTE associated with the use of low‐dose (less than 50 μg ethinyl estradiol) COCs containing different progestogens.Search strategy: PubMed and the Cochrane Library were searched from database inception through September 15, 2016, by combining search terms for oral contraception and venous thrombosis.Selection criteria: Studies reporting VTE risk estimates among healthy users of progestogen‐containing low‐dose COCs were included.Data collection and analysis: A random‐effects model was used to generate pooled adjusted risk ratios and 95% confidence intervals; subgroup and sensitivity analyses assessed the impact of monophasic‐COC use and study‐level characteristics.Main results: There were 22 articles included in the analysis. The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel‐containing COCs (pooled risk ratios 1.5–2.0). The analysis restricted to monophasic COC formulations with 30 μg of ethinyl estradiol yielded similar findings. After adjustment for study characteristics, the risk estimates were slightly attenuated.Conclusions: Compared with the use of levonorgestrel‐containing COCs, the use of COCs containing other progestogens could be associated with a small increase in risk for VTE.
- Open Access
- 22 September 2017
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 66 (37) , 990-994
Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection
CDC adopts updated guidance for the U.S. Medical Eligibility Criteria for Contraceptive Use.
- 22 September 2017
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 66 (37) , 990-994
Open AccessUpdate to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection
CDC adopts updated guidance for the U.S. Medical Eligibility Criteria for Contraceptive Use.